Inside information
November 27[th], 2020 at
Nanoform launches technology for biologics and sets new near-term business target for 2021
As drug molecules become more complex so do the options to deliver them. This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform's reach into the growing biological market. The technology is in its early stages of development and a patent application has recently been filed with the
Prof. Edward Hæggström, Nanoform CEO: "Small is powerful, also in Bio! We are committed to improving patients' lives and supporting our pharmaceutical partners in developing the best medicines possible. Having established our CESS[®] small molecule nanoparticle technology to GMP, we continue to focus on delivering value for our partners and now we can extend our partnerships into supporting their biological programs. There are significant challenges in drug development in this space and we look forward to working closely with pharma and biotech partners to discover how we can add value to their programs, provide patient benefit and competitive product differentiation."
Prof.
Telephone conference for analysts, investors, and media:
In connection with this release and Nanoform's Q3 report release (Nov 27[th] at
The presentation will be broadcast live as a webcast available at: https://financialhearings.com/event/13383 (https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Ffinancialhearings.com%2Fevent%2F13383&data=04%7C01%7C%7C8a5c8dd32daf4019b18c08d8871632b6%7C70e2685be6cc4120935cc2b4e1d1915b%7C0%7C0%7C637407876708354730%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=nChexXsqwlZs4%2FVoIYOlbOyPAc1vnTa1ENf7RqX5Eo0%3D&reserved=0)
Teleconference dial-in numbers:
For further information, please contact:
Prof. Edward Hæggström, CEO
edward.haeggstrom@nanoform.com / +358 29 370 0150
For investor relations queries, please contact:
hvh@nanoform.com / +46 7686 650 11
The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules' formulation performance through its nanoforming services. Nanoform's capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks specified in Nanoform's prospectus published (on
https://news.cision.com/nanoform/r/nanoform-launches-technology-for-biologics-and-sets-new-near-term-business-target-for-2021,c3244565
https://mb.cision.com/Main/18905/3244565/1340597.pdf
(c) 2020 Cision. All rights reserved., source